-
NRL-3 is being developed as a non-invasive acute therapy to stop seizures that have progressed to status epilepticus, a life-threatening seizure emergency.*
-
NRL-3 is a proprietary intranasal formulation of benzodiazepine in a pre-dosed, pre-filled delivery system, designed to be administered by a medical professional as an alternative to intravenously administered medication.
-
The proprietary formulation of NRL-3 leverages the Neurelis technology platform in an effort to address some of the common challenges frequently encountered with intranasal delivery of benzodiazepines.
-
NRL-3 is in the initial (formulation) stage of development and presents a worldwide commercial opportunity for Neurelis.
*NRL-3 is an investigational product candidate that has not been approved by FDA for any indication.